Latest Drug Safety Monitoring News

Page 1 of 1
Syntara has reported statistically significant exploratory results for its Parkinson’s-related drug SNT-4728, while advancing blood-cancer and scar studies. The quarter also brought A$4.7 million in R&D funding, but the liquidation of a former buyer threatens a facility relocation and recovery of about A$0.6 million.
Ada Torres
Ada Torres
30 Oct 2026
Dimerix Limited’s ACTION3 Phase 3 trial for DMX-200 in treating FSGS kidney disease has passed its sixth independent safety review with no concerns, reinforcing the drug’s promising safety profile.
Ada Torres
Ada Torres
22 May 2025

Browse the archive

Full archive